For research use only. Not for therapeutic Use.
SRI-29329（Cat No.:I036625）is a selective small molecule compound that acts as an antagonist of the dopamine D4 receptor. It has garnered attention in the research community for its potential therapeutic applications in psychiatric disorders, particularly in the treatment of conditions like schizophrenia and attention deficit hyperactivity disorder (ADHD). By modulating dopaminergic signaling, SRI-29329 may help alleviate symptoms associated with these disorders. Its selectivity for the D4 receptor distinguishes it from other dopamine antagonists, potentially reducing side effects commonly associated with broader-spectrum dopaminergic treatments, making it a promising candidate for further exploration in clinical studies.
| Catalog Number | I036625 |
| CAS Number | 2086809-58-5 |
| Synonyms | SRI-29329; SRI 29329; SRI29329; |
| Molecular Formula | C20H26ClN7 |
| Purity | 98% |
| Solubility | Soluble in DMSO |
| Appearance | Solid powder |
| Storage | Store at -20°C |
| IUPAC Name | 2-N-[(1S,2S)-2-aminocyclohexyl]-6-N-(3-chlorophenyl)-9-propan-2-ylpurine-2,6-diamine |
| InChI | InChI=1S/C20H26ClN7/c1-12(2)28-11-23-17-18(24-14-7-5-6-13(21)10-14)26-20(27-19(17)28)25-16-9-4-3-8-15(16)22/h5-7,10-12,15-16H,3-4,8-9,22H2,1-2H3,(H2,24,25,26,27)/t15-,16-/m0/s1 |
| InChIKey | JPJBCKSRGYPABG-HOTGVXAUSA-N |
| SMILES | CC(C)N1C=NC2=C(N=C(N=C21)N[C@H]3CCCC[C@@H]3N)NC4=CC(=CC=C4)Cl |
| Reference | 1: Shi Y, Park J, Lagisetti C, Zhou W, Sambucetti LC, Webb TR. A triple exon-skipping luciferase reporter assay identifies a new CLK inhibitor pharmacophore. Bioorg Med Chem Lett. 2017 Feb 1;27(3):406-412. doi: 10.1016/j.bmcl.2016.12.056. Epub 2016 Dec 24. Erratum in: Bioorg Med Chem Lett. 2017 Mar 15;27(6):1488-1489. PubMed PMID: 28049589; PubMed Central PMCID: PMC5295499. |
